Graham Healthcare Group Acquires InTeliCare Health Services, Expanding Personalized Home Health Care Offering into Florida

Graham Healthcare Group | December 21, 2021

Graham Healthcare Group, a leader in homecare, palliative and hospice services, today announced its acquisition of InTeliCare Health Services, a provider of home health services in central Florida. The agreement was finalized on December 15th, 2021, and marks Graham's first expansion into Florida.

Graham will integrate InTeliCare into its Residential Home Health division to accelerate access to personalized home health care throughout Florida. Residential is a leading post-acute home care network serving communities in Michigan, Illinois and Pennsylvania.

Integrating InTeliCare into Residential Home Health will bring together industry-leading, patient-centered home health services to strengthen the continuum of care for patients across central Florida. 

"More than one-fifth of Florida's population is over 65, and that number continues to grow. With the baby boomer generation doubling in size and an increase in comorbidities, this is an ideal time for Graham Healthcare Group to begin serving people in the state of Florida in their own homes with high-quality post-acute and end-of-life care." 

David Curtis, Chief Executive Officer of Home Health at Graham Healthcare Group

"With the addition of InTeliCare, we're poised for growth as we continue our mission to transform home care and improve patient experiences," Curtis said. "This agreement expands the ability of Graham Healthcare Group to deliver consistent, high-quality care across the spectrum of home health and further strengthens our foundation for success."

Irene Tuttle, InTeliCare Founder and Chief Executive Officer, will serve in an advisory role following the deal's close. Toni Walker, InTeliCare's longstanding Vice President of Operations, will maintain leadership over day-to-day operations. 

"We strongly align with Residential's values of care and community," Tuttle said. "This is an extraordinary opportunity to join forces with an organization that shares our employee- and patient-driven approach to care."

"We are confident that the powerful synergies and added strength this partnership creates will continue to elevate the value and experience of post-acute care and advance the continuum of home health care in central Florida," Tuttle added.

Residential Home Health intends to retain InTelicare's workforce and will support them with enhanced operational efficiencies and advanced clinical and technology innovations. 

Both Residential Home Health and InTeliCare are known for strong, employee-friendly cultures. Residential has been recognized as a top workplace for 11 consecutive years in the Detroit market and was recognized in the Chicago and St. Louis markets in 2021.

About Graham Healthcare Group

A subsidiary of Graham Holdings Company, Graham Healthcare Group has designed business and technology solutions to drive better care, outcomes and productivity in home health and hospice services for more than 20 years. It includes Residential Healthcare Group, Allegheny Health Network-Healthcare @ Home, Mary Free Bed at Home, Clarus, and CSI Pharmacy. It is deeply committed to radically changing the home care model by putting patients and their families at the top of the paradigm, while enhancing the quality and consistency of healthcare in the most convenient and cost-effective setting possible: at home.  

About Residential Home Health

 Based in Troy, Michigan, Residential Home Health is a leading provider of home health, palliative and hospice services in Michigan, Illinois and Pennsylvania. Residential is one of the fastest growing home health networks with 2,500 dedicated care professionals. 

About InTeliCare Health Services 

Based in Boca Raton, InTeliCare is a leading provider of home health services in central Florida. The company has 80 employees serving nearly 300 patients from three offices.


Toluna used their global influencer community and QuickSurveys platform to survey more than 1000 consumers in the United States. View the full infographic to see what we found.


Toluna used their global influencer community and QuickSurveys platform to survey more than 1000 consumers in the United States. View the full infographic to see what we found.

Related News


Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Cellulite

SofWave Medical, Ltd. | December 20, 2022

Sofwave Medical Ltd an emerging leader in energy-based non-invasive, aesthetic medical devices announced the U.S. Food and Drug Administration’s clearance of Sofwave’s SUPERB™ technology to be used for the short-term improvement in the appearance of cellulite. Dr. Shimon Eckhouse, Chairman & Co-Founder commented on the occasion, “We are pleased to receive FDA clearance to use the Company's proprietary SUPERB™ technology to improve the appearance of cellulite in the short term. Non-invasive treatment of cellulite is one of the most desired body treatments in medical aesthetics because of the high prevalence of cellulite in women of all ages and the lack of effective and safe solutions with no patient down-time. Sofwave has shown once again that its investment in the development of the SUPERB™ technology to treat highly prevalent aesthetic indications bears significant fruit and will support the continued rapid growth of the Company. Our disruptive SUPERB™ technology was designed to be efficient and easy to use, and the Company invests and plans to continue investing in bringing innovative solutions to the growing aesthetic technology market generating great ROI to our physician customers.” In the clinical trials submitted to the FDA as part of the 510(k) application in support of the cellulite FDA clearance, the Company conducted a multi-site clinical study that evaluated the safety and effectiveness of the device for the non-invasive dermatological aesthetic improvement in cellulite appearance. A total of 68 women were treated at 4 sites in the United States. Eligible patients received 2 treatments using SUPERB™ technology on one side (right or left) of the lateral / posterior upper thigh or buttocks. Serial clinical photographs were collected under standardized conditions before treatment and at the 3-month follow-up visits. Photographs were assessed by blinded independent reviewers to identify pre-treatment images when compared to post treatment images and to grade the pre-treatment and post-treatment images using the Cellulite Severity Scale (CSS). Improvement was also evaluated using the Global Aesthetic Improvement Scale (GAIS) and Laxity Scale (LS). Safety assessments included evaluation of adverse events via physician examination during and after the treatment. Post-study, the blinded reviewers correctly identified the post treatment images for 89% of the subjects. No serious or unanticipated adverse event was reported during the study. “The FDA's clearance of SUPERB™ for use in cellulite could not have come at a timelier moment. Our dedicated U.S. direct sales force is positioned to expand our growing presence and market share of the aesthetic medical device market in the U.S. In addition, our recent regulatory clearance in Brazil further extends our global footprint, letting us immediately launch sales in this important and sizeable market. Furthermore, our partnership in China with HTDK, one of Asia's strongest healthcare solutions providers, covers our expansion in that territory. Our focused commitment across these major markets, will go a long way towards further accelerating global sales and brand-recognition of our devices in the upcoming new year.” Lou Scafuri, Sofwave's CEO In 2021, the FDA cleared additional indications for SUPERB™ technology, for lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental neck regions. In addition, the Sofwave SUPERB™ technology is also cleared by the U.S. FDA for a non-invasive dermatological aesthetic treatment to improve facial lines and wrinkles. About SUPERB™ Sofwave’s state-of-the-art SUPERB™ Technology addresses the growing demand for non-invasive treatments that deliver noticeable results in non-invasive treatment of highly desired aesthetic indications. The device’s cooled transducers are directly coupled to the epidermis, creating a unique 3D array of volumetric thermal zones that deliver parallel energy simultaneously, heating precisely at the right depth in the mid-dermis. A single Sofwave treatment reduces facial wrinkles in a fast 30 to 45 minute non-invasive treatment with no interruption to a patient’s daily routine or post-treatment discomfort. About Sofwave Medical Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue and the short term improvement in the appearance of cellulite providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients.

Read More


Vivante Health Avails Cognitive Behavioral Therapy on GIThrive Health Platform

Vivante Health | January 11, 2023

On January 10, 2023, Vivante Health revealed the expansion of its digestive health platform, GIThrive, by including a cognitive behavioral therapy (CBT) digital therapeutic that aims to help users address conditions such as irritable bowel syndrome (IBS). The new feature, known as IThrive, becomes the first CBT solution to be incorporated into a holistic digestive health platform and has been shown to reduce healthcare costs while improving participants' well-being. Informed by the specific conditions of GIThrive's users, the new feature will let users benefit from a host of online tools for CBT, such as individual attention from a dedicated health coach and registered dietitian, daily audio sessions for ten weeks that teach CBT skills and techniques, guided meditation and breathing techniques for digestive health, evidence-based coping strategies, journaling, and other daily exercises. Developed by clinical health psychologists, all IThrive components follow clinically validated CBT best practices to assist users in adjusting their behaviors and changing dysfunctional thinking patterns to help relieve symptoms of IBS and other digestive disorders. Multiple independent studies have shown that CBT effectively relieves IBS symptoms, including one randomized controlled trial, in which, 90% of patients who used online CBT reported symptom improvement. In the latter study, 60% of participants reported a significant improvement in their symptoms. IThrive is the first in a series of digital therapeutics that Vivante intends to add to its gut health platform to provide increasingly customized solutions for digestive disease patients. The feature expands on the core capabilities of the GIThrive platform, which offers evidence-based clinical pathways to help people suffering from chronic digestive conditions and their symptoms. The platform combines the research of gut bacteria and identification of trigger foods with app-based individualized action plans, food diaries, educational resources, and 24/7 personal assistance from trained dietitians and health coaches. In addition, the platform is supported by a multidisciplinary group of gastroenterologists, microbiome scientists, and other clinical experts. After a year, one non-profit employer that implemented the GIThrive platform witnessed a 15% decrease in digestive-related healthcare expenses, a 70% self-reported improvement in participants' health, and an 89% improvement in participants' general well-being, benefiting both employees and the employer's bottom line. About Vivante Health Chicago-based Vivante Health, established in 2016, is a digital healthcare business reimagining gut-first chronic disease management. GIThrive, the company's all-in-one gut health service, uses easy-to-use technology, superior research, and on-demand human support to enhance digestive health and save costs. The company focuses on digestive disease because it affects an astounding 70 million Americans, double the number of people with diabetes, and more than many otherchronic conditions combined.

Read More


SimiTree Announces Afia and GreenpointMed Acquisition

SimiTree | January 13, 2023

SimiTree has strengthened its position in the US behavioral health support market by acquiring two new companies. On January 12, 2023, Bill Simione, CEO and Managing Principal of SimiTree, announced the acquisition of behavioral health data analytics and consulting firm Afia and Florida-based credentialing service provider GreenpointMed. This move enhances the full range of support services offered by SimiTree and its behavioral health flagship, Infinity Behavioral Health Services. Afia employs data-driven decision-making to address business challenges by streamlining EHR implementations, optimizing revenue cycles, promoting clinical best practices, and developing IT infrastructures to advance behavioral businesses. SimiTree's leading data analytics capabilities are enhanced by this acquisition, allowing clients to benefit from tech-enabled optimization of financial, clinical, and operational functions and gain greater insight from actionable data. Acquiring GreenpointMed has allowed SimiTree to expand billing and debt recovery capabilities and offer time-saving credentialing services with insurance panels to behavioral health providers. GreenpointMed has substantial credentialing experience in every state, with all insurers, including Medicare and Medicaid. "This move delivers the scalability SimiTree needs to address the behavioral health industry's growing need for our services as we head into 2023," said Bill Simone. He further added, "We remain committed to providing a robust array of services to assist behavioral health providers in developing a stronger revenue cycle with improved cash flow, higher collection rates, and best-in-class processes." (Source – PR Newswire) About SimiTree Formed by the merger of Simione Healthcare Consultants with BlackTree Healthcare Consulting in 2021, SimiTree provides clinical, financial, operational consulting and outsourced services such as review choice demonstration (RCD), OASIS, billing, coding, and quality assessment and performance improvement (QAPI). Headquartered in King of Prussia (Pennsylvania), the company aligns its teams, services, and approach with clients' challenges to help them improve operational performance, fulfill clinical and financial potential, and improve the organization's overall health.

Read More